On Monday, the FDA removed the clinical hold on Novavax Inc.’s (NASDAQ:NVAX) Investigational New Drug (IND) application for ...

The seasonal flu places a significant burden on healthcare systems globally, leading to over five million hospitalizations ...

The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...

and stand-alone influenza vaccine candidates. The FDA has cleared the Company to begin enrolling the planned Phase 3 trial ...

“The Phase 1 clinical trial is designed to evaluate the safety, reactogenicity, and immunogenicity of ARCT-2304 as a potential vaccine to protect against the highly pathogenic H5N1 avian influenza.” ...

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

Novavax (NVAX) announced that the U.S. FDA has removed the clinical hold on Novavax’s Investigational New Drug application for its ...

Researchers at NextGen, a part of MU Health Care, are innovating flu vaccine strategies that could lead to cancer treatment.

(RTTNews) - Novavax, Inc. (NVAX) Monday said the Food and Drug Administration or FDA has removed the clinical hold on its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine ...

The aTIV vaccine provides better protection against influenza-related medical encounters than the HD-TIV vaccine in high-risk older adults.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M adjuvant, today ...

Investing.com -- The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s ...